[Effect of combination chemotherapy of 5'-DFUR, cyclophosphamide and tamoxifen in a case of advanced breast cancer].
A patient with inoperable, advanced cancer in left breast and metastasis in the opposite axillary lymph nodes, received combination of 5'-DFUR, cyclophosphamide and tamoxifen. The daily dosages were: 1,200 mg/body, 100 mg/body, and 20 mg/body respectively, 5'-DFUR and cyclophosphamide were intermittently administered for two weeks followed by two weeks resting. The original foci began to respond after 3 weeks from the start of this therapy and disappeared in the 27th week. The metastatic foci disappeared in the 16th week, when the patient presented significant improvement from the aspect of quality of life with a good appetite. No serious side effects were observed except for leukocytopenia. This study indicated that the said combination is useful in treatment of advanced/recurrent breast cancer.
Enomoto
T
T
Dept. of Internal Medicine, Suita City Hospital.
Watanabe
A
A
D002293:Adenocarcinoma, Scirrhous / Q000188:drug therapy* / Q000473:pathology; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D008207:Lymphatic Metastasis; D013629:Tamoxifen / Q000008:administration & dosage
D005467:Floxuridine; D013629:Tamoxifen; D003520:Cyclophosphamide; C025034:doxifluridine